The vaccine was recently approved for Phase 3 clinical trials after showing promising results in Phase 1 and Phase 2.
Healthcare workers administer covid-19 vaccine to men during a special vaccination drive on the grounds of a public school in Hyderabad, India, on Sunday, May 30, 2021. (AP Photo / Mahesh Kumar) A.)
The Federal Ministry of Health has finally decided on an arrangement with Biological-E, a vaccine manufacturer based in Hyderabad. COVID-19 (New Coronavirus Infection) Prepaid vaccine dose of Rs 1500 crore.These vaccines will be manufactured and stockpiled by Biological-E from August to December of this year, a statement from the ministry said Thursday. COVID-19 (New Coronavirus Infection) The Biological-E vaccine is currently undergoing Phase 3 clinical trials after showing promising results in Phase 1 and Phase 2 trials. The vaccine being developed by Biological-E is an RBD protein subunit vaccine that may be available in the coming months.
The Biological-E proposal was reviewed and recommended for approval after due diligence by a national group of experts on vaccine management. COVID-19 (New Coronavirus Infection) (NEGVAC), the statement said.
He said the deal with Biological-E is part of the Center’s broader efforts to encourage indigenous vaccine manufacturers by providing support and financial support in research and development.
Biological-E COVID vaccine candidates are supported by the Center from preclinical to Phase 3 studies.
The Biotechnology Division not only provided financial support in terms of grants of over 1 billion rupees, but also partnered with Biological-E to partner with the Institute’s Translational Health Science Technology Institute (THSTI), Faridabad.
This is the government’s “Mission COVID Slaksha, Indians COVID-19 (New Coronavirus Infection) Launched to strengthen and accelerate the “Vaccine Development Mission” COVID-19 (New Coronavirus Infection) According to the statement, vaccine development efforts as part of the third stimulus package, Atmanirbhar 3.0.
The mission is to provide citizens with safe, effective and affordable accessibility. COVID-19 (New Coronavirus Infection) vaccine.The mission is to support the development of 5-6 COVID-19 (New Coronavirus Infection) Vaccine candidate. Some of these are currently approaching licensing and implementation of public health systems.
Not just accelerated COVID-19 (New Coronavirus Infection) In addition to vaccine development efforts, we have also fostered a robust end-to-end vaccine development ecosystem in the country that can be used for other ongoing and future research and development activities of other vaccines.
Health ministry buys 30 cr COVID-19 vaccine doses from Biological-E for Rs 1,500 cr-India News , Firstpost Source link Health ministry buys 30 cr COVID-19 vaccine doses from Biological-E for Rs 1,500 cr-India News , Firstpost